Netherlands Court Rules in Biosensors' Favor; Declines Injunction Request by Angiotech and Boston Scientific

    SINGAPORE, Jan. 30 /PRNewswire/ -- Biosensors International Group, Ltd.
 (Bloomberg: BIG SP) today announced that it has successfully defended against
 legal claims and defeated a request for an injunction request brought against
 it in the court in The Hague by Vancouver, BC-based Angiotech Pharmaceuticals
 Inc and Boston Scientific.  The result of the court's decision to deny the
 claims and injunction allows Biosensors to continue the production of its
 Axxion(TM) drug eluting stent ("DES") in the Netherlands with distribution
 throughout Europe and other parts of the world where regulatory approval for
 the device has been secured.
     The legal action, commenced on December 9, 2005 in The Netherlands,
 claimed that the Axxion(TM) stent infringes on European patent No. 0706376
 (the "European Patent") which is jointly owned by Angiotech and the University
 of British Columbia.  Boston Scientific is the exclusive licensee of the
 European Patent for cardiovascular medicine, which encompasses, among other
 things, claims describing a stent that uses a composition of Paclitaxel and a
 polymeric coating as a drug carrier.  The judge ruled that Biosensors
 Axxion(TM) DES does not infringe the European Patent.
     Yoh-Chie Lu, Chairman and CEO of Biosensors said, "We are obviously very
 pleased with the Court's decision in this matter as the decision of the Dutch
 court enables us to continue to sell the Axxion(TM) DES and to pursue our
 business model.  The introduction and roll out of Axxion(TM) in Europe has
 been an important step for Biosensors as it has allowed us to build our sales
 and marketing infrastructure, initiate market share and develop the necessary
 systems for the eventual launch of our flagship BioMatrix(TM) DES.
 BioMatrix(TM) features a fully biodegradable polymer and our own proprietary
 drug, and we plan for it to drive our growth in the coming years."
     Mr. Lu further noted that the legal action only involved its Axxion(TM)
 product and does not relate to BioMatrix(TM), which is expected to receive CE
 Mark approval in the first half of 2006.
 
     About Biosensors International Group, Ltd.
     Biosensors develops, manufactures and markets innovative medical devices
 used in interventional cardiology and critical care procedures.  Biosensors is
 well-positioned to emerge as a leader in drug-eluting stents, an evolving
 therapy that is rapidly gaining market share from traditional therapies such
 as bare-metal stenting and open-heart surgery.  Biosensors has internally
 developed technology to address each component of a drug-eluting stent system,
 including a stent, a stent delivery catheter, a bioresorbable polymer and a
 proprietary anti-restenotic drug.  It is pursuing two separate drug-eluting
 stent programs, BioMatrix(TM) and Axxion(TM), and has licensed aspects of its
 drug-eluting stent technology to four companies.
 
     Forward-Looking Statements
     Certain statements herein include forward-looking statements within the
 meaning of the U.S. Private Securities Litigation Reform Act of 1995.
 Forward-looking statements generally can be identified by the use of
 forward-looking terminology, such as "may," "will," "expect," "intend,"
 "estimate," "anticipate," "believe," "project" or "continue" or the negative
 thereof or other similar words.  All forward-looking statements involve risks
 and uncertainties, including, but not limited to, customer acceptance and
 market share gains, competition from companies that have greater financial
 resources; introduction of new products into the marketplace by competitors;
 successful product development; dependence on significant customers; the
 ability to recruit and retain quality employees as Biosensors grows; and
 economic and political conditions globally.  Actual results may differ
 materially from those discussed in, or implied by, the forward-looking
 statements.  The forward-looking statements speak only as of the date of this
 release and Biosensors assumes no duty to update them to reflect new, changing
 or unanticipated events or circumstances.
 
     Media Contact
 
     Biosensors International Group
     Ms. Tina Lim, Executive, Corporate Communications
     Tel:  (65) 6213 5712
     Email:  media@biosensors.com
 
     Media Relations / Investor Relations Firm
 
     Allen & Caron Inc.
     Mr. Matt Clawson
     Executive Vice President, Investor Relations
     Tel:  (1) 949 474 4300
     Email:  matt@allencaron.com
 
 

SOURCE Biosensors International Group, Ltd.

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.